Neurolite is a drug owned by Lantheus Medical Imaging Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 11, 2012. Details of Neurolite's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5431900 | Ester-substituted diaminedithiols and radiolabeled complexes thereof |
Jul, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Neurolite is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Neurolite's family patents as well as insights into ongoing legal events on those patents.
Neurolite's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Neurolite's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 11, 2012 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Neurolite Generics:
There are no approved generic versions for Neurolite as of now.
Alternative Brands for Neurolite
Neurolite which is used for imaging and diagnosing medical conditions through radioimaging., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Ge Healthcare |
| |||
About Neurolite
Neurolite is a drug owned by Lantheus Medical Imaging Inc. It is used for imaging and diagnosing medical conditions through radioimaging. Neurolite uses Technetium Tc-99M Bicisate Kit as an active ingredient. Neurolite was launched by Lantheus Medcl in 1994.
Approval Date:
Neurolite was approved by FDA for market use on 23 November, 1994.
Active Ingredient:
Neurolite uses Technetium Tc-99m Bicisate Kit as the active ingredient. Check out other Drugs and Companies using Technetium Tc-99m Bicisate Kit ingredient
Treatment:
Neurolite is used for imaging and diagnosing medical conditions through radioimaging.
Dosage:
Neurolite is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | INJECTABLE | Prescription | INJECTION |